
Celcuity (CELC), a clinical-stage biotechnology company, has quietly surged more than 215% year-to-date, turning heads on Wall Street.
While larger names in oncology dominate headlines, this under-the-radar cancer drug developer is making a name for itself by advancing an innovative approach to treating hormone receptor-positive, HER2-negative (HR+/HER2−) breast cancer, one of the most common and deadly subtypes of breast cancer.